Sugi Predict

Sugi Predict / Targets / PTEN

PTEN

Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN · P60484 · PTEN on Sugi Atlas →

350 patent compounds predicted against PTEN, 284 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL70271 SCHEMBL70271 0.67 1/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL10982620) 0.65 1/20
SCHEMBL8435278 SCHEMBL8435278 0.61 1/20
SCHEMBL65250 SCHEMBL65250 0.59 1/20
SCHEMBL4407150 SCHEMBL4407150 0.59 1/20
SCHEMBL9051375 SCHEMBL9051375 0.59 1/20
SCHEMBL29563859 SCHEMBL29563859 0.59 1/20
SCHEMBL30638471 SCHEMBL30638471 0.59 1/20
SCHEMBL31336237 SCHEMBL31336237 0.59 1/20
SCHEMBL6586 SCHEMBL6586 0.57 1/20
SCHEMBL80581 SCHEMBL80581 0.57 1/20
SCHEMBL334758 SCHEMBL334758 0.57 1/20
SCHEMBL360723 SCHEMBL360723 0.57 1/20
SCHEMBL456436 SCHEMBL456436 0.57 1/20
SCHEMBL1206832 SCHEMBL1206832 0.57 1/20
SCHEMBL1207329 SCHEMBL1207329 0.57 1/20
SCHEMBL2016247 SCHEMBL2016247 0.57 1/20
SCHEMBL3242805 SCHEMBL3242805 0.57 1/20
SCHEMBL3360788 SCHEMBL3360788 0.57 1/20
SCHEMBL3674500 SCHEMBL3674500 0.57 1/20

Clinical trials — most relevant to PTEN by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Addition of Everolimus to Standard of Care in Carcinoma Gallbladder PHASE2/PHASE3RECRUITING
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer PHASE1/PHASE2RECRUITING
Sirolimus to Treat Cowden Syndrome and Other PTEN Hamartomatous Tumor Syndromes PHASE2COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients PHASE2COMPLETED
RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid PHASE2COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
Rapamycin Treatment for Activated Phosphoinositide 3-Kinase δ Syndrome PHASE1/PHASE2COMPLETED
Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Osimertinib Plus Capivasertib in NSCLC With PIK3CA/AKT1/PTEN Alterations Following Prior 1L Osimertinib PHASE1/PHASE2NOT_YET_RECRUITING
Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer PHASE2UNKNOWN
Temsirolimus in Treating Patients With Locally Advanced or Metastatic Breast Cancer PHASE2COMPLETED
Trial of BKM120/Tamoxifen-combination in Patients With HR-pos, HER2-neg Breast Cancer PHASE2COMPLETED
A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss PHASE2RECRUITING
Open Label Study of Everolimus (RAD001) in Patients With Segmental Overgrowth Syndrome PHASE2WITHDRAWN
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab) PHASE1COMPLETED
Study of the Combination of BKM120 and Cisplatin or Carboplatin in Patients With Advanced Solid Tumors PHASE1COMPLETED
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers PHASE1COMPLETED
Palliative Thoracic Radiotherapy Plus BKM120 PHASE1COMPLETED
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery PHASE1COMPLETED
Partial PTEN Deletion in Breast Cancer nanUNKNOWN
NGS in Gallbladder Cancer and Response to Treatment nanRECRUITING
Molecular Analysis in Tissue Samples From Patients With Advanced or Metastatic Neuroendocrine Tumors nanUNKNOWN
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma nanCOMPLETED
PIK3CA in HER2+ BC and pCR Trial nanUNKNOWN
Studying Tumor Tissue Samples From Patients With Early-Stage Breast Cancer nanWITHDRAWN
Duality of Lipids: the Athlete's Paradox nanCOMPLETED
The Study Aims to Investigate the Effects of Oral Inositols on Insulin-resistance in Children With Obesity. nanUNKNOWN
CircularRNA-microRNA-mRNA Regulatory Axis in IVF nanNOT_YET_RECRUITING
PTEN and Organ-Specific microRNAs in Metastatic Breast Cancer nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a PTEN binder may also engage these)

ProteinNameSimilarity
P60483 — 1.000 P60483 →
O54857 — 1.000 O54857 →
O08586 — 1.000 O08586 →
Q9PUT6 — 0.996 Q9PUT6 →
MTMR1 Phosphatidylinositol-3-phosphate phosphatase MTMR1 0.966 landscape →
Q9Z2C4 — 0.966 Q9Z2C4 →
RNGTT mRNA-capping enzyme 0.962 landscape →
O55236 — 0.962 O55236 →
PTPN4 Tyrosine-protein phosphatase non-receptor type 4 0.961 landscape →
Q9WU22 — 0.960 Q9WU22 →
Q9QW07 — 0.958 Q9QW07 →
A6QLT2 — 0.957 A6QLT2 →
Q9Z2D1 — 0.957 Q9Z2D1 →
Q5REB9 — 0.956 Q5REB9 →
Q7ZY60 — 0.955 Q7ZY60 →
Q9Z1F9 — 0.955 Q9Z1F9 →
Q6NY98 — 0.954 Q6NY98 →
Q642Q1 — 0.954 Q642Q1 →
Q07722 — 0.954 Q07722 →
UBA2 SUMO-activating enzyme subunit 2 0.954 landscape →
Q8BPM2 — 0.953 Q8BPM2 →
Q13614 — 0.952 Q13614 →
Q9MYN5 — 0.952 Q9MYN5 →
Q4V7N2 — 0.952 Q4V7N2 →
MAP4K5 Mitogen-activated protein kinase kinase kinase kinase 5 0.952 landscape →
Q641K1 — 0.952 Q641K1 →
Q15147 — 0.952 Q15147 →
A0FKG7 — 0.951 A0FKG7 →
Q9UPW5 — 0.951 Q9UPW5 →
O82656 — 0.951 O82656 →